Patents by Inventor Kevin Hunt

Kevin Hunt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazinone compounds and uses thereof
    Patent number: 12240831
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 12240833
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20250034170
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: January 30, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen, Jeremiah Brittin, Zhiquan Lei, Greg Sheyka
  • Pyridazinone compounds and uses thereof
    Patent number: 12202819
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: January 21, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5
    Publication number: 20240417725
    Abstract: In some embodiments, the present disclosure provides compositions of antisense oligonucleotides (ASOs) such as gapmer ASOs for inhibition of complement C5 expression. Further, in some embodiments, such ASOs are useful for treating diseases associated with complement C5 dysfunction. Where a sequence is complementary to an intron of a complement 05 pre-mRNA.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 19, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Maria Nguyen, Daniel Ysselstein, Carole Deyts
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20240262832
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease. Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease. Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 8, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20240246952
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 25, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng
  • Pyridazinone compounds and uses thereof
    Patent number: 12012395
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 18, 2024
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20240025879
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 11873290
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 16, 2024
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES
    Publication number: 20230159513
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 25, 2023
    Inventors: Kevin Koch, Kevin Hunt, Stephen Schlachter, Alan Russell
  • PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES
    Publication number: 20230150977
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 18, 2023
    Inventors: Kevin Koch, Kevin Hunt, Stephen Schlachter, Alan Russell
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20230048816
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: May 27, 2022
    Publication date: February 16, 2023
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Grace UZOHO, Chris STEELE
  • Pyridazinone compounds and uses thereof
    Patent number: 11390606
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: July 19, 2022
    Assignee: Edgewise Therapecutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
  • Benzimidazole compounds as HDAC6 inhibitors
    Patent number: 11339150
    Abstract: Novel compounds of Formula I are described, where the compounds are selective HDAC6 inhibitors suitable for treatment of diseases associated with HDAC6, where X, Y, Z, A1, A2, Q1 and Q2 are as described.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 24, 2022
    Assignee: OnKure, Inc.
    Inventors: Anthony D. Piscopio, Gan Zhang, Kevin Hunt
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220106291
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: June 11, 2021
    Publication date: April 7, 2022
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220081410
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 17, 2022
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Chris STEELE, Grace UZOHO
  • BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS
    Publication number: 20220041584
    Abstract: Novel compounds of Formula I are described, where the compounds are selective HDAC6 inhibitors suitable for treatment of diseases associated with HDAC6, where X, Y, Z, A1, A2, Q1 and Q2 are as described.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 10, 2022
    Applicant: OnKure, Inc.
    Inventors: Anthony D. Piscopio, Gan Zhang, Kevin Hunt
  • Pyridazinone compounds and uses thereof
    Patent number: 11236065
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Edgewise Therapecutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele, Grace Uzoho
  • Pyridazinone compounds and uses thereof
    Patent number: 11091464
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: August 17, 2021
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele